CME: Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)

Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)

Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)

A symposium focusing on EPA, remnant cholesterol, clinical trials on omega-3 fatty acids in ASCVD, mechanism of action, and guideline recommendations.

Available credits: 0.75

Time to complete: 45 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This activity provides an opportunity to evaluate the clinical value of recent, large-scale randomized clinical trials on the management of patients at high risk of having atherosclerotic cardiovascular disease (ASCVD) events. One of those trials, REDUCE-IT, showed dramatic reductions in ASCVD events for patients with clinical ASCVD or diabetes and ≥1 risk factors, and the use of purified eicosapentaenoic acid (EPA) in these patients has recently been recommended in several guidelines. Professor Michel Farnier from CHU Dijon Bourgogne in France and Professor Børge Nordestgaard from Copenhagen University Hospital in Denmark share their thoughts on this important topic.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 


    Michel Farnier, MD, PhD
    IRCV and Department of Cardiology
    CHU Dijon Bourgogne
    Dijon, France

    Consulting Fees: Abbott, Akcea/Ionis, Amarin, Amgen, Daiichi Sankyo, Kowa,
    Merck & Co., Mylan, Pfizer, Sanofi/Regeneron, Servier
    Clinical Trials: Amgen, Regeneron, Sanofi/Regeneron

    Børge G. Nordestgaard, MD, DMSc
    Professor, Chief Physician
    Hospital/University: Copenhagen University Hospital, University of Copenhagen
    Herley, Copenhagen

    Consulting Fees: Akcea, Amarin, Amgen, AstraZeneca, Denka Seiken, Kowa, Novartis, Novo Nordisk, Regeneron, Sanofi, Silence Therapeutics

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD, has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain why high-risk patients with increased triglyceride levels remain at high cardiovascular risk despite controlled LDL-cholesterol
    • Describe the spectrum of omega-3 fatty acids undergoing large-scale ASCVD outcomes trials
    • Appreciate the different effects of omega-3 fatty acids and their formulations on ASCVD events, including the negative role of dietary supplements
  • Target Audience

    This educational activity is designed for preventive/clinical cardiologists, endocrinologists, internists, general practitioners, and other healthcare professionals involved in cardiovascular prevention, primary care, and rehabilitation.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free